|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
5120
|
Provisional Schedule
| Committee meeting |
06 June 2024 |
| Expected publication |
14 August 2024 |
Project Team
Email enquiries
| External Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors |
AstraZeneca (osimertinib) |
| Others |
Department of Health and Social care |
| |
NHS England |
| Patient carer groups |
EGFR Positive UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
Bristol Myers Squibb (paclitaxel) |
| |
Hospira - CAU not returned, not participating |
| |
Medac - CAU not returned, not participating |
| |
Pierre Fabre - CAU not returned, not participating |
| |
Sandoz - CAU not returned, not participating |
| |
Seacross Pharmaceuticals - CAU not returned, not participating |
| |
Sun Pharmacueticals - CAU not returned, not participating |
| |
Synchrony Pharma - CAU not returned, not participating |
| |
Teva - CAU not returned, not participating |
| General commentators |
All Wales Therapeutic and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare Products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
25 October 2023
|
Invitation to participate |
|
07 September 2023 - 04 October 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
04 July 2023
|
In progress. Topic in appraisal. |
For further information on our processes and methods, please see our CHTE processes and methods manual